National Institutes of Health

Description

This FOA encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Who can apply

• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• For-profit organizations other than small businesses
• Small businesses

Contact

NIH OER Webmaster <br/>FBOWebmaster@OD.NIH.GOV <br/>
FBOWebmaster@OD.NIH.GOV